By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Incyte Corporation 

1801 Augustine Cut-Off

Wilmington  Delaware  19803  U.S.A.
Phone: 1-855-446-2983 Fax: n/a


Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Our first commercial product, Jakafi®, is approved in the U.S. for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Science and Innovation

At Incyte, science drives success. Our world-class expertise, investment in sound and precise science, and our rigorous pursuit of R&D drive our efforts to identify new molecules with the potential to improve the lives of patients, make a difference in health care, and build sustainable value for all our stakeholders.


We are committed to positively impacting the lives of patients with cancer and other diseases. Our clinical research is held to the highest standards of scientific and ethical rigor and we strive to implement programs and initiatives to remove any possible barriers to access for our medicines.

Compliance and Transparency

We aim to make a difference—for patients, medical professionals, organizations, the broader healthcare community and all our global stakeholders. To achieve these goals, we are committed to conducting business ethically. We hold ourselves accountable to the highest standards to ensure that all of our interactions are conducted appropriately. We regularly review and amend our practices according to our own standards, as well as the standards required of us by the communities in which we live and work.

Our Global Community

We exist to improve the lives of people facing life-altering and life-threatening diseases like cancer, and actively support various local and global initiatives that are health-related or benefit the communities in which we live and work.

We strive to comply with all laws and regulations that govern environmental, health and safety matters and to sustainable business practices.

Key Statistics

Ownership: Public

Web Site: Incyte
Symbol: INCY

Company News
Incyte (INCY) To Report Third Quarter Financial Results 10/14/2016 12:10:18 PM
Why Incyte (INCY), Biogen (BIIB) and BioMarin (BMRN) are Hot Acquisition Targets 10/12/2016 6:02:21 AM
Incyte (INCY) Release: Additional Phase I Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-Naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda (Pembrolizumab) 10/7/2016 10:35:48 AM
Q Biomed Comments On Its Glaucoma Drug And Industry News In The Ophthalmology Space 10/7/2016 8:51:18 AM
Incyte (INCY) Release: Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda (Pembrolizumab) 9/28/2016 11:27:33 AM
Incyte (INCY) Supports Those Affected By Rare Blood Cancers On MPN Awareness Day And Throughout Blood Cancer Awareness Month 9/8/2016 11:14:19 AM
Incyte (INCY) To Present At Upcoming Investor Conferences 8/30/2016 11:25:01 AM
Forbes Magazine Names Incyte (INCY) To Its List Of World’s Most Innovative Companies For Second Consecutive Year 8/25/2016 9:41:36 AM
Incyte (INCY) Reports 2016 Second-Quarter Financial Results And Updates Key Clinical Programs 8/9/2016 11:07:04 AM
Updated Data For Epacadostat, Incyte (INCY)’s Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016 7/19/2016 12:13:17 PM